Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study.

Arthritis research & therapy·2026
Same author

Increased expression of Toll-like receptors and associated alarmins in temporal arteries of patients with giant cell arteritis.

Molecular medicine (Cambridge, Mass.)·2025
Same author

[S2e guidelines on the treatment of polymyalgia rheumatica: update 2024 : Evidence-based guidelines of the German Society for Rheumatology and Clinical Immunology (DGRh), the Austrian Society for Rheumatology and Rehabilitation (ÖGR) and the Swiss Society for Rheumatology (SGR) and the participating medical scientific specialist societies and other organizations].

Zeitschrift fur Rheumatologie·2025
Same author

Early referral of patients with suspected polymyalgia rheumatica - A systematic review.

Seminars in arthritis and rheumatism·2023
Same author

Raman spectroscopy for postmortem interval estimation of human skeletal remains: A scoping review.

Journal of biophotonics·2023
Same author

Association of ultrasound-confirmed axillary artery vasculitis and clinical outcomes in giant cell arteritis.

Seminars in arthritis and rheumatism·2022

Related Experiment Video

Updated: May 17, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

[Giant-cell arteritis: update: diagnosis and therapy].

M Schirmer1, C Dejaco, W A Schmidt

  • 1Labor für Molekulare Biologie und Rheumatologie, Allgemeine Ambulanz und Rheumaambulanz, Univ.-Klinik für Innere Medizin I, Medizinische Universität Innsbruck, Anichstr. 35, 6020, Innsbruck, Österreich. michael.schirmer@i-med.ac.at

Zeitschrift Fur Rheumatologie
|November 10, 2012
PubMed
Summary

Giant-cell arteritis (GCA), a common vasculitis in older adults, often affects extracranial arteries. Early diagnosis and treatment with glucocorticoids, methotrexate, and aspirin are crucial for preventing severe complications like vision loss.

Related Experiment Videos

Last Updated: May 17, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Context:

  • Giant-cell arteritis (GCA) is the most prevalent vasculitis affecting individuals over 50.
  • Vision loss is a common severe complication, though extracranial artery involvement, including the aorta, is more frequent than previously recognized.

Purpose:

  • To review the current understanding of GCA, encompassing its epidemiology, pathophysiology, diagnostic challenges, imaging modalities, and therapeutic strategies.
  • To highlight the diagnostic difficulties due to the lack of specific laboratory tests and the importance of imaging in assessing vascular involvement.

Summary:

  • The pathophysiology involves dendritic and T-cells, suggesting an antibody presence, but a definitive link to infections remains unproven.
  • While blood inflammatory markers are often elevated, specific diagnostic tests for GCA are lacking.
  • Diagnostic imaging, including ultrasonography, MRI, and FDG-PET, aids in localizing and determining the extent of vascular inflammation.

Impact:

  • Glucocorticoids remain the standard GCA treatment, with methotrexate potentially reducing cumulative dosage.
  • Acetylsalicylic acid is recommended for prophylaxis of cardiovascular and cerebrovascular events and for managing associated osteoporosis.